Mathias Rummel
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 67
- Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment 85
- Hematology top 0.5%
- Platelet Disorders and Treatments 16
- Blood groups and transfusion 10
- Oncology top 1%
- Viral-associated cancers and disorders 19
- CAR-T cell therapy research 9
- Neurology top 2%
-
- Acute Lymphoblastic Leukemia research 12
-
- Lung Cancer Treatments and Mutations 9
- Co-authors
- Dieter HoelzerBruce D. ChesonEckhart WeidmannDorothea Kofahl-KrauseWolfram BruggerParis S. MitrouJuergen BarthManfred Welslau
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
Mathias Rummel
124 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Genetics 2.2k
- Pathology and Forensic Medicine 3.1k
- Hematology 1.6k
- Oncology 2.1k
- Neurology 534
Countries citing papers authored by Mathias Rummel
This map shows the geographic impact of Mathias Rummel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mathias Rummel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mathias Rummel more than expected).
Fields of papers citing papers by Mathias Rummel
This network shows the impact of papers produced by Mathias Rummel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mathias Rummel. The network helps show where Mathias Rummel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mathias Rummel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 18 | |
| 3 | 2023 | 13 | |
| 4 | 2022 | 0 | |
| 5 | 2022 | 15 | |
| 6 | 2021 | 3 | |
| 7 | 2021 | 11 | |
| 8 | 2020 | 4 | |
| 9 | 2018 | 6 | |
| 10 | 2014 | 13 | |
| 11 | 2013 | 203 | |
| 12 | 2013 | 20 | |
| 13 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialbreakdown → | 2013 | 962 |
| 14 | 2011 | 41 | |
| 15 | 2011 | 3 | |
| 16 | 2011 | 14 | |
| 17 | 2009 | 303 | |
| 18 | 2006 | 27 | |
| 19 | 2003 | 26 | |
| 20 | 2000 | 18 |
About Mathias Rummel
Mathias Rummel is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology, having authored 128 papers that have together received 5.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (85 papers), Chronic Lymphocytic Leukemia Research (67 papers), Viral-associated cancers and disorders (19 papers), Platelet Disorders and Treatments (16 papers), Acute Lymphoblastic Leukemia research (12 papers), Blood groups and transfusion (10 papers), Lung Cancer Treatments and Mutations (9 papers) and CAR-T cell therapy research (9 papers). The work is most often cited by research in Genetics (2.2k citations), Pathology and Forensic Medicine (3.1k citations) and Hematology (1.6k citations). Mathias Rummel has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Dieter Hoelzer, Bruce D. Cheson, Eckhart Weidmann, Dorothea Kofahl-Krause, Wolfram Brugger, Paris S. Mitrou, Juergen Barth, Manfred Welslau, Ulrich von Grünhagen and Ulrich Kaiser. Their work appears in journals such as Blood, Journal of Clinical Oncology, Seminars in Oncology, British Journal of Haematology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.